World of DTC Marketing https://validator.w3.org/feed/docs/rss2.html No,Washington Won’t Ban Pharma TV Ads $39,800 a Month for a Cancer Pill: When Does the Price of Innovation Become Too High? A Breakthrough in Pancreatic Cancer — But Will Patients Be Able to Afford It? Pharma Needs to Change—Because Healthcare Is Changing Faster Than Pharma A Quick Guide to Influencing Senior Executives as a Pharma Marketer Great Pharma DTC Marketers Leave the Spreadsheet and Listen to Patients Pharma Sold America on Weight Loss. It Forgot to Tell Patients About Muscle. Mounjaro.com Is More Than a Drug Website — It’s a Look at the Future of Pharma Marketing Should Employers Cover GLP-1 Drugs? The Answer Isn’t as Simple as Yes or No Finally, Some Evidence Employers Can Use to Justify Covering GLP-1s No, You Can’t Hide Promotion Inside “Unbranded” Disease Education Yale Single-Payer Health Study: Pros and Cons Heidi Overton Is the Wrong Choice for FDA Commissioner The Unsustainable Cost of Healthcare: A Voter’s Primary Concern Stop Counting MSL Calls: The Best Ways to Evaluate Medical Affairs and MSLs Pharma’s Experience Problem: When “Yes” Becomes More Valuable Than Judgment The Healthcare Squeeze Is Coming for the American Paycheck How Much Has AbbVie Cost U.S. Healthcare by Gaming the Patent System? If We Love Working in Pharma, Why Are We So Afraid to Speak Up About What’s Wrong With It? Pharma Has More Data Than Ever. So Why Are We Still Surprised by the Market? If Pharma Wants Employers to Cover GLP-1s, Prove They Lower Total Healthcare Costs How Many of Us Can Actually Afford Cancer Care? Why Is Pharma Still Making the Same Mistakes in Leadership and Hiring? Medical Affairs Has a Leadership Problem Information Asymmetry Is One of the Business Models Underlying American Healthcare Employers Can Take Control of Healthcare Costs — They Just Have to Stop Playing Defense Anymore Pharma’s $5 Billion Question: What Value Does a Sales Representative Actually Add? Medical Affairs Is Losing Its Way—and Pharma’s Hiring Practices Are Making It Worse Zenbexus: Is BMS Bringing the Future of Multiple Myeloma—or Revlimid 2.0—to a Market That Has Already Moved On? Americans Agree Health Care Is Broken.. Are Prescription Drug Prices Really Falling? Not So Fast. We’re Paying For Universal Healthcare Already How Do We Recognize the Patient-Centered Marketers in Pharma? What Physicians Really Think About Big Pharma Pharma Marketers Are Measuring the Campaign—and Missing the Patient Pharma’s Oncology Targeting Model Is Missing Part of the Care Team The Best Way to Reach Physicians Online? Stop Trying to “Reach” Them. Pharma Is Spending Billions on New Drugs—Then Trying to Save Money on the People Who Explain the Science FDA Enforcement Letters Should Be Required Reading for Every Pharma Marketer AI Can Recommend the Treatment. But Who Owns the Decision? Does Pharma Care What GLP-1s Are Doing to Employer Healthcare Costs? While RFK Jr. Obsesses Over Food Dyes, Americans Are Getting Sick From Their Food My Predictions for the GLP-1 Market If a Drug Has a Boxed Warning, It Shouldn’t Be Advertised on TV For Pharma, LinkedIn Has Become A PR Bulletin Board Mark Cuban Didn’t Just Lower Drug Prices. He Exposed the Business Model. PR Releases On Prior Authorizations Don’t Tell A Story Some Drugs Shouldn’t Be Sold Between Commercial Breaks. Evenity Is One of Them. Novo Nordisk Didn’t Lose to a Better Drug. It Lost to a Faster Company You Can Do Everything Right in America—and Cancer Can Still Bankrupt You